FDA Greenlights Gene Therapy, Because Patience Isn’t a Drug
In a plot twist worthy of a soap opera, the FDA announced it’s 'clearing the way' for Sarepta Therapeutics to resume shipments of their gene therapy for Duchenne muscular dystrophy to some patients. Yes, just some, because apparently miracles come with fine print. The FDA’s official line? They’re 'clearing the way,' which sounds a bit like popping open a space in traffic, except this lane could save lives. Gene therapy shipments resumed, but if you were hoping for a full-on party, well, it’s more of a dignified nod: progress served with a side of bureaucratic seasoning.
Share the Story
(1 of 3)FDA finally said 'go' for gene therapy shipments, or as they put it, 'clearing the way.' Someone tell my delivery app to work on that kind of speed. #MiracleMiles
Oh look, FDA is 'clearing the way' for some shipments like it's GPS rerouting around traffic jams. Your gene therapy might arrive sometime between now and the heat death of the universe.
Resuming gene therapy shipments to some patients is like giving only half your friends passes to the Electric Daisy Carnival—exclusive, selective, and sure to cause FOMO.
Source: Statnews | Published: 7/28/2025 | Author: Adam Feuerstein
More Articles in Health
Motorola Razr Flip Phones Finally Told They’re Secure Enough for 2027
KPMG’s Consulting Business Dies Dramatically While Staff Take a Hike
America Tries Staying Cool While Secretly Preparing For Wattocalypse
90-Year-Old Dad Outsources Bathing to Jovial Nigerian and Ghanaian Carers
Woman Ages Backwards in Online Writing Class, Still Loses to 21-Year-Old
Billionaire’s Daughter’s Brain Hemorrhage Detected Belatedly By $299 Ring
Dietitians Unite to Demand We Eat More Beans, Save Humanity from Boredom
Mark Cuban Declares AI Too Empathetic to Replace Doctors, Only Bullshit Jobs Fear
